MINIMALLY INVASIVE GLAUCOMA SURGERY: EFFICACY, SAFETY, AND CLINICAL OUTCOMES OF THE MAIN SURGICAL TECHNIQUES

Authors

Keywords:

glaucoma; minimally invasive glaucoma surgery; intraocular pressure; drainage devices; safety; phacoemulsification

Abstract

DOI: https://doi.org/10.46296/yc.v10i19.1028

Abstract

Background: Minimally invasive glaucoma surgery (MIGS) comprises tissue-sparing procedures aimed at enhancing aqueous humor outflow. Clinical appraisal must distinguish intraocular pressure (IOP) control, medication reduction, and complications. Objective: To critically assess the effectiveness and safety of major MIGS procedures in adults, considering devices, comparators, and duration of follow-up. Methods: Structured literature review of reports published through August 20, 2026. PubMed/MEDLINE and SciELO records were assessed, with supplementary exploration of regional BVS/LILACS-accessible literature and reference lists. Randomized trials, systematic reviews, and safety-focused cohorts were prioritized. Narrative synthesis was undertaken without a new meta-analysis or unverified PRISMA counts. Results: In HORIZON, 66% of eyes receiving Hydrus plus cataract surgery were medication-free at five years versus 46% of eyes receiving cataract surgery alone. In the pivotal iStent inject trial, 75.8% versus 61.9% achieved at least 20% unmedicated IOP reduction at two years. The nonrandomized GEMINI cohort reported sustained OMNI outcomes. XEN45 provided less mean IOP lowering than trabeculectomy but required fewer postoperative interventions in a randomized trial. Safety outcomes varied by mechanism and included hyphema, IOP spikes, obstruction, hypotony, reinterventions, and device-specific endothelial injury. Conclusions: MIGS can reduce IOP and/or medication burden in selected patients, particularly those with mild-to-moderate open-angle glaucoma undergoing cataract extraction. Comparative effectiveness and long-term safety remain device-specific, requiring individualized selection and surveillance.

Keywords: glaucoma; minimally invasive glaucoma surgery; intraocular pressure; drainage devices; safety; phacoemulsification.

Downloads

Download data is not yet available.

References

Gallo Afflitto G, Swaminathan SS. Minimally Invasive Glaucoma Surgery. Int Ophthalmol Clin. 2023;63(4):33-60. doi:10.1097/IIO.0000000000000479.

Vemulapalli K, Gandhewar R, Yim TW, Virgili G, Bicket AK, Bunce C, et al. Minimally invasive trabecular meshwork surgery for open-angle glaucoma. Cochrane Database Syst Rev. 2026;7:CD015186. doi:10.1002/14651858.CD015186.pub2.

Samuelson TW, Chang DF, Marquis R, Flowers B, Lim KS, Ahmed IIK, et al. A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. Ophthalmology. 2019;126(1):29-37. doi:10.1016/j.ophtha.2018.05.012.

Ahmed IIK, De Francesco T, Rhee D, McCabe C, Flowers B, Gazzard G, et al. Long-term outcomes from the HORIZON randomized trial for a Schlemm’s canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-751. doi:10.1016/j.ophtha.2022.02.021.

Samuelson TW, Sarkisian SR Jr, Lubeck DM, Stiles MC, Duh YJ, Romo EA, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811-821. doi:10.1016/j.ophtha.2019.03.006.

Greenwood MD, et al. Canaloplasty and trabeculotomy combined with phacoemulsification for glaucoma: 12-month results of the GEMINI study. Clin Ophthalmol. 2022;16:1225-1234. doi:10.2147/OPTH.S362932.

Greenwood MD, Yadgarov A, Flowers BE, Sarkisian SR Jr, Ohene-Nyako A, Dickerson JE Jr. 36-month outcomes from the prospective GEMINI study: canaloplasty and trabeculotomy combined with cataract surgery for patients with primary open-angle glaucoma. Clin Ophthalmol. 2023;17:3817-3824. doi:10.2147/OPTH.S446486.

Ahmed IIK, Vera V, Stalmans I, Fea AM, Mansouri K, Gu X, et al. Effectiveness and safety of the XEN45 gel stent compared to trabeculectomy in primary open-angle glaucoma: the Gold-Standard Pathway Study. BMJ Open Ophthalmol. 2025;10(1):e001696. doi:10.1136/bmjophth-2024-001696.

Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology. 2021;128(12):1710-1721. doi:10.1016/j.ophtha.2021.05.023.

Lima FL, Diniz-Filho A, Suzuki Júnior ER. Procedimentos minimamente invasivos para glaucoma: uma revisão atualizada da literatura. Rev Bras Oftalmol. 2022;81. doi:10.37039/1982.8551.20220105.

Justiniano MJ, Mura JJ, Giampani Junior J, Silva MJL, Fong GB. Surgical procedures in glaucoma: a preferred practice pattern report by the Latin American Glaucoma Society. Arq Bras Oftalmol. 2026;89(1):e20250109. doi:10.5935/0004-2749.2025-0109.

US Food and Drug Administration. Alcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucoma [Internet]. Silver Spring: FDA; 2018 [consultado 10 nov 2026]. Disponible en: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/alcon-announces-voluntary-global-market-withdrawal-cypass-micro-stent-surgical-glaucoma

American Academy of Ophthalmology. Reporting clinical endpoints in studies of minimally invasive glaucoma surgery [Internet]. San Francisco: AAO; 2025 [consultado 10 nov 2026]. Disponible en: https://www.aao.org/education/clinical-statement/reporting-clinical-endpoints-in-studies-of-minimal

Published

2026-10-30

How to Cite

Astudillo-Ochoa, P. V., Choez-Abendaño, Y. I., Choez-Abendaño, N. D., & Vizñay-Mendieta, N. N. (2026). MINIMALLY INVASIVE GLAUCOMA SURGERY: EFFICACY, SAFETY, AND CLINICAL OUTCOMES OF THE MAIN SURGICAL TECHNIQUES. REVISTA CIENTÍFICA MULTIDISCIPLINARIA ARBITRADA YACHASUN - ISSN: 2697-3456, 10(19), 2013–2025. Retrieved from https://editorialibkn.com/index.php/Yachasun/article/view/1119